RT Journal Article
SR Electronic
T1 Characterising long term Covid-19: a living systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.08.20246025
DO 10.1101/2020.12.08.20246025
A1 Melina Michelen
A1 Vincent Cheng
A1 Lakshmi Manoharan
A1 Natalie Elkheir
A1 Drew Dagens
A1 Claire Hastie
A1 Margaret O’Hara
A1 Jake C. Suett
A1 Dania T. Dahmash
A1 Polina Bugaeva
A1 Ishmeala Rigby
A1 Daniel Munblit
A1 Eli Harriss
A1 Amanda Burls
A1 Carol Foote
A1 Janet T. Scott
A1 Gail Carson
A1 Piero Olliaro
A1 Louise Sigfrid
A1 Charitini Stavropoulou
YR 2021
UL http://medrxiv.org/content/early/2021/05/31/2020.12.08.20246025.abstract
AB Background While it is now apparent clinical sequelae (often called Long Covid) may persist after acute Covid-19, their nature, frequency, and aetiology are poorly characterised. This study aims to regularly synthesise evidence on Long Covid characteristics, to inform clinical management, rehabilitation, and interventional studies to improve long term outcomes.Methods A living systematic review. Medline, CINAHL (EBSCO), Global Health (Ovid), WHO Global Research Database on Covid-19, LitCOVID, and Google Scholar were searched up to 17th March 2021. Published studies including at least 100 people with confirmed or clinically suspected Covid-19 at 12 weeks or more post-onset were included. Results were analysed using descriptive statistics and meta-analyses to estimate prevalence with 95% confidence intervals (CIs).Results Thirty-nine studies were included: 32 cohort, six cross-sectional, and one case-control. Most showed high or moderate risk of bias. None were set in low-income countries, limited studies included children. Studies reported on 10,951 people (48% female) in 12 countries. Most followed-up post hospital discharge (78%, 8520/10951). The longest mean follow-up was 221.7 (SD: 10.9) days post Covid-19 onset. An extensive range of symptoms with wide prevalence was reported, most commonly weakness (41%; 95% CI 25% to 59%), malaise (33%; 95% CI 15% to 57%), fatigue (31%; 95% CI 24% to 39%), concentration impairment (26%; 95% CI 21% to 32%), and breathlessness (25%; 95% CI 18% to 34%). Other frequent symptoms included musculoskeletal, neurological, and psychological. 37% (95% CI 18% to 60%) of people reported reduced quality of life.Conclusion Long Covid is a complex condition with heterogeneous symptoms. The nature of the studies precludes a precise case definition or evaluation of risk factors. There is an urgent need for prospective, robust, standardised controlled studies into aetiology, risk factors, and biomarkers to characterise Long Covid in different at-risk populations and settings.Systematic review registration The protocol was prospectively registered on the PROSPERO database (CRD42020211131).Section 1: What is already known?A significant number of people continue to describe ongoing symptoms long after the acute phase of Covid-19, often referred to as Long Covid.Long Covid is a heterogeneous condition with an uncertain prevalence, for which there is currently no precise case definition.Section 2: What are the new findings?This ‘living’ systematic review provides a comprehensive summary of peer-reviewed published evidence on persistent symptoms of Covid-19 and will be regularly updated as new evidence emerges.The breadth of reported symptoms suggests a complex, heterogeneous condition affecting both those who were hospitalised and those managed in the community.Our review identifies weakness (41%; 95% CI 25% to 59%), general malaise (33%; 95% confidence interval 15% to 57%), fatigue (31%; 95% CI 24% to 39%), concentration impairment (26%; 95% CI 21% to 32%) and breathlessness (25%; 95% CI 18% to 34%) as the most common symptoms.Section 3: What do the new findings imply?The current evidence base of the clinical spectrum of Long Covid is limited, based on heterogenous data, and vulnerable to biases, hence caution should be used when interpreting or generalising the results.Our review identifies areas where further Long Covid research is critically needed to help characterise Long Covid in different populations and define its aetiology, risk factors, and biomarkers, as well as the impact on variants of concern and vaccination on long term outcomes.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. JCS declares he is an individual living with long-term symptoms of probably covid-19. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]. The results presented have been obtained with the financial support of the EU FP7 project PREPARE (602525).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics approval was neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on the paperADLActivities of daily livingAKIAcute kidney injuryCOVID-19Coronavirus DiseaseDCLODiffusion capacity for carbon monoxideICUIntensive care unitIQRInterquartile RangeISARICInternational Severe Acute Respiratory and emerging Infection ConsortiumLMICLow-middle income countryLSRLiving’ systematic reviewNICENational Institute for Health and Care ExcellenceNIHRNational Institute for Health ResearchPTSDpost traumatic stress disorderRoBRisk of biasSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2SDStandard deviationVASVisual Analogue Scale